Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOPRANO-CD
NCT05169593Phase 4Recruiting
- Sponsor
- UZ Leuven
- Start
- Sep 2022
- Primary completion
- Oct 2027
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial in Crohn's disease (2 arms), sponsored by UZ Leuven. Primary endpoints: Postoperative endoscopic recurrence (Rutgeerts score ≥i2b) at 86 weeks and Need for unscheduled treatment adaptation prior to week 86. Started Sep 2022; status: recruiting.
02
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05169593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05169593.